Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.
2.

A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.

Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R; IMPAACT P1056 Team.

Pediatr Infect Dis J. 2010 Oct;29(10):940-4. doi: 10.1097/INF.0b013e3181e2189d.

3.

Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.

Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K.

Pharmacotherapy. 2004 Apr;24(4):453-9.

PMID:
15098798
4.

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.

Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, Schultze ME, Woods L, Loewen DF, Kaul S, et al.

Pediatrics. 1995 Aug;96(2 Pt 1):247-52.

PMID:
7630678
5.

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S, Fraser W, Back D, Khoo S.

J Antimicrob Chemother. 2009 Dec;64(6):1251-9. doi: 10.1093/jac/dkp358. Epub 2009 Oct 6.

6.

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW.

Antimicrob Agents Chemother. 2000 Apr;44(4):1029-34.

7.

A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings.

Weidle PJ, Abrams EJ, Gvetadze R, Rivadeneira E, Kline MW.

Pediatr Infect Dis J. 2006 Jan;25(1):59-64.

PMID:
16395105
8.

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.

Gatti G, Vigano' A, Sala N, Vella S, Bassetti M, Bassetti D, Principi N.

Antimicrob Agents Chemother. 2000 Mar;44(3):752-5.

9.

Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.

Innes S, Norman J, Smith P, Smuts M, Capparelli E, Rosenkranz B, Cotton M.

Antivir Ther. 2011;16(7):1131-4. doi: 10.3851/IMP1876.

PMID:
22024529
10.

Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.

Jullien V, Raïs A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M, Rey E, Pons G, Blanche S, Tréluyer JM.

Br J Clin Pharmacol. 2007 Jul;64(1):105-9. Epub 2007 Feb 26.

11.

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.

Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N.

AIDS. 2005 Sep 23;19(14):1495-9.

PMID:
16135903
12.

Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children.

Wang LH, Wiznia AA, Rathore MH, Chittick GE, Bakshi SS, Emmanuel PJ, Flynn PM.

Antimicrob Agents Chemother. 2004 Jan;48(1):183-91.

13.

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.

Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, Calles NR, Kirkpatrick SB, Simon C.

J Pediatr. 1998 Mar;132(3 Pt 1):543-6.

PMID:
9544920
14.

Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Sy SK, Malmberg R, Matsushima A, Asin-Prieto E, Rosenkranz B, Cotton MF, Derendorf H, Innes S.

Int J Antimicrob Agents. 2015 Apr;45(4):413-9. doi: 10.1016/j.ijantimicag.2014.12.016. Epub 2015 Jan 19.

15.

The pharmacokinetics of nelfinavir in HIV-1-infected children.

van Heeswijk RP, Scherpbier HJ, de Koning LA, Heymans HS, Lange JM, Beijnen JH, Hoetelmans RM.

Ther Drug Monit. 2002 Aug;24(4):487-91.

PMID:
12142631
16.

Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE Jr, Abrams EJ, Mofenson LM.

Pediatrics. 1999 May;103(5):e62.

PMID:
10224206
17.

Dose-related activity of stavudine in patients infected with human immunodeficiency virus.

Petersen EA, Ramírez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, Peterson DM, Cross A, Anderson RE, Dunkle LM.

J Infect Dis. 1995 Mar;171 Suppl 2:S131-9.

PMID:
7861018
18.

Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.

Grasela DM, Stoltz RR, Barry M, Bone M, Mangold B, O'Grady P, Raymond R, Haworth SJ.

Antimicrob Agents Chemother. 2000 Aug;44(8):2149-53.

19.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM.

Pediatrics. 1996 Jun;97(6 Pt 1):886-90.

PMID:
8657531
20.

Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.

Kline MW, Calles NR, Simon C, Schwarzwald H.

Pediatr Infect Dis J. 2000 Nov;19(11):1083-6.

PMID:
11099091
Items per page

Supplemental Content

Write to the Help Desk